公开(公告)号：US20210246191A1

公开(公告)日：2021-08-12

申请号：US16972794

申请日：2019-06-06

Applicant: BioNTech SE

Inventor： Ugur Sahin ,  Bonny Gaby Lui ,  Nadja Salomon ,  Joycelyn Wüstehube-Lausch ,  Matin Daneschdar ,  Hans-Ulrich Schmoldt ,  Markus Fiedler

IPC: C07K14/78 ,  C07K1/107 ,  G01N33/68 ,  G01N33/574

Abstract: The present invention relates to the diagnosis and treatment of diseases expressing Fibronectin Extra Domain B (EDB) such as diseases characterized by tissue remodeling and/or angiogenesis, in particular cancerous diseases, such as head and neck, brain, colorectal, lung, prostate and breast cancer. More particularly, the invention concerns peptides targeting Fibronectin Extra Domain B.

公开(公告)号：US11673939B2

公开(公告)日：2023-06-13

申请号：US16972794

申请日：2019-06-06

Applicant: BioNTech SE

Inventor： Ugur Sahin ,  Bonny Gaby Lui ,  Nadja Salomon ,  Joycelyn Wüstehube-Lausch ,  Matin Daneschdar ,  Hans-Ulrich Schmoldt ,  Markus Fiedler

IPC: C07K14/78 ,  C07K1/107 ,  G01N33/574 ,  G01N33/68 ,  A61K38/00

CPC classification number: C07K14/78 ,  C07K1/1075 ,  G01N33/574 ,  G01N33/68 ,  A61K38/00

Abstract: The present invention relates to the diagnosis and treatment of diseases expressing Fibronectin Extra Domain B (EDB) such as diseases characterized by tissue remodeling and/or angiogenesis, in particular cancerous diseases, such as head and neck, brain, colorectal, lung, prostate and breast cancer. More particularly, the invention concerns peptides targeting Fibronectin Extra Domain B.

公开(公告)号：US20240002471A1

公开(公告)日：2024-01-04

申请号：US18303642

申请日：2023-04-20

Applicant: BioNTech SE

Inventor： Ugur Sahin ,  Bonny Gaby Lui ,  Nadja Salomon ,  Joycelyn Wüstehube-Lausch ,  Matin Daneschdar ,  Hans-Ulrich Schmoldt ,  Markus Fiedler

IPC: C07K14/78 ,  C07K1/107 ,  G01N33/574 ,  G01N33/68

CPC classification number: C07K14/78 ,  C07K1/1075 ,  G01N33/574 ,  G01N33/68 ,  A61K38/00

Abstract: The present invention relates to the diagnosis and treatment of diseases expressing Fibronectin Extra Domain B (EDB) such as diseases characterized by tissue remodeling and/or angiogenesis, in particular cancerous diseases, such as head and neck, brain, colorectal, lung, prostate and breast cancer. More particularly, the invention concerns peptides targeting Fibronectin Extra Domain B.